190 related articles for article (PubMed ID: 22333599)
1. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.
Eberhard J; Gaber A; Wangefjord S; Nodin B; Uhlén M; Ericson Lindquist K; Jirström K
Br J Cancer; 2012 Feb; 106(5):931-8. PubMed ID: 22333599
[TBL] [Abstract][Full Text] [Related]
2. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
Nodin B; Johannesson H; Wangefjord S; O'Connor DP; Lindquist KE; Uhlén M; Jirström K; Eberhard J
Diagn Pathol; 2012 Aug; 7():115. PubMed ID: 22935204
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.
Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J
J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression and significance of SATB2 protein in colorectal cancer.
Cígerová V; Adamkov M; Drahošová S; Grendár M
Ann Diagn Pathol; 2021 Jun; 52():151731. PubMed ID: 33894556
[TBL] [Abstract][Full Text] [Related]
5. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
6. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer.
Wang S; Zhou J; Wang XY; Hao JM; Chen JZ; Zhang XM; Jin H; Liu L; Zhang YF; Liu J; Ding YQ; Li JM
J Pathol; 2009 Sep; 219(1):114-22. PubMed ID: 19557828
[TBL] [Abstract][Full Text] [Related]
7. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
8. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.
Mezheyeuski A; Ponten F; Edqvist PH; Sundström M; Thunberg U; Qvortrup C; Pfeiffer P; Sorbye H; Glimelius B; Dragomir A
Acta Oncol; 2020 Mar; 59(3):284-290. PubMed ID: 31769323
[No Abstract] [Full Text] [Related]
9. Special AT-rich sequence-binding protein 2 acts as a negative regulator of stemness in colorectal cancer cells.
Li Y; Liu YH; Hu YY; Chen L; Li JM
World J Gastroenterol; 2016 Oct; 22(38):8528-8539. PubMed ID: 27784965
[TBL] [Abstract][Full Text] [Related]
10. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
[TBL] [Abstract][Full Text] [Related]
11. SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.
Mansour MA; Hyodo T; Akter KA; Kokuryo T; Uehara K; Nagino M; Senga T
Oncotarget; 2016 Jan; 7(4):4993-5006. PubMed ID: 26701851
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of SATB2 immunohistochemical expression in colorectal cancer versus primary ovarian mucinous neoplasms.
Maguire B; Duggan WP; Prehn JHM; Burke JP
Ann Diagn Pathol; 2024 Aug; 71():152302. PubMed ID: 38642469
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
Larsson A; Johansson ME; Wangefjord S; Gaber A; Nodin B; Kucharzewska P; Welinder C; Belting M; Eberhard J; Johnsson A; Uhlén M; Jirström K
Br J Cancer; 2011 Aug; 105(5):666-72. PubMed ID: 21829192
[TBL] [Abstract][Full Text] [Related]
14. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
Magnusson K; de Wit M; Brennan DJ; Johnson LB; McGee SF; Lundberg E; Naicker K; Klinger R; Kampf C; Asplund A; Wester K; Gry M; Bjartell A; Gallagher WM; Rexhepaj E; Kilpinen S; Kallioniemi OP; Belt E; Goos J; Meijer G; Birgisson H; Glimelius B; Borrebaeck CA; Navani S; Uhlén M; O'Connor DP; Jirström K; Pontén F
Am J Surg Pathol; 2011 Jul; 35(7):937-48. PubMed ID: 21677534
[TBL] [Abstract][Full Text] [Related]
15. Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer.
Hrudka J; Matěj R; Nikov A; Tomyak I; Fišerová H; Jelínková K; Waldauf P
Sci Rep; 2022 Nov; 12(1):19152. PubMed ID: 36351995
[TBL] [Abstract][Full Text] [Related]
16. SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer.
Gu J; Wang G; Liu H; Xiong C
Cell Prolif; 2018 Aug; 51(4):e12455. PubMed ID: 29701273
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients.
Liu TR; Xu LH; Yang AK; Zhong Q; Song M; Li MZ; Hu LJ; Chen FJ; Hu ZD; Han P; Zeng MS
PLoS One; 2012; 7(7):e40704. PubMed ID: 22815795
[TBL] [Abstract][Full Text] [Related]
18. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling.
Mansour MA; Hyodo T; Ito S; Kurita K; Kokuryo T; Uehara K; Nagino M; Takahashi M; Hamaguchi M; Senga T
FEBS J; 2015 Apr; 282(8):1394-405. PubMed ID: 25662172
[TBL] [Abstract][Full Text] [Related]
19. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
Lyn J; Wang Y; Wang F; Shen M; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
